Haematologica (Apr 2018)
Single-agent dabrafenib for BRAFV600E-mutated histiocytosis
- Ankush Bhatia,
- Gary Ulaner,
- Raajit Rampal,
- David M. Hyman,
- Omar Abdel-Wahab,
- Benjamin H. Durham,
- Ahmet Dogan,
- Neval Ozkaya,
- Mario E. Lacouture,
- Julio Hajdenberg,
- Chezi Ganzel,
- Eli L. Diamond
Affiliations
- Ankush Bhatia
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Gary Ulaner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Raajit Rampal
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- David M. Hyman
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Omar Abdel-Wahab
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Benjamin H. Durham
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Ahmet Dogan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Neval Ozkaya
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Mario E. Lacouture
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Julio Hajdenberg
- University of Florida Health Cancer Center at Orlando Health, FL, USA
- Chezi Ganzel
- Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
- Eli L. Diamond
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- DOI
- https://doi.org/10.3324/haematol.2017.185298
- Journal volume & issue
-
Vol. 103,
no. 4
Abstract
No abstracts available.
